

Biomarkers

Part 1: Technologies & Applications

By

Prof. K.K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

July 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

July 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	27
1. Introduction	29
Definitions	29
Historical aspects of biomarkers.....	29
Classification of biomarkers.....	30
Biomarker as a response to therapeutic intervention	31
Pharmacokinetic/pharmacodynamics biomarkers	31
Predictive biomarkers	31
Valid biomarkers.....	32
Types of biomarkers	33
Genes as biomarkers.....	33
<i>Silent gene mutations.....</i>	<i>33</i>
Epigenetic biomarkers	33
Exosomes as biomarkers	34
Proteins as biomarkers	34
<i>Proteomics.....</i>	<i>35</i>
DNA biomarkers	35
Mitochondrial DNA	35
<i>Mitochondrial mutations.....</i>	<i>35</i>
RNA biomarkers.....	36
<i>Transcriptomics</i>	<i>36</i>
<i>MicroRNAs</i>	<i>37</i>
Metabolomics	37
Glycomics	38
Single nucleotide polymorphisms	38
<i>Haplotyping.....</i>	<i>39</i>
Cell biomarkers of disease	39
Stem cell biomarkers.....	39
<i>Association of stem cell biomarkers with disease.....</i>	<i>40</i>
<i>Cancer stem cell biomarkers.....</i>	<i>40</i>
<i>Endoglin as a functional biomarker of stem cells</i>	<i>40</i>
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	<i>40</i>
<i>Protein expression profile as biomarker of stem cells.....</i>	<i>41</i>
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	<i>41</i>
<i>SSEA-4 as biomarker of MSCs</i>	<i>41</i>
Gaseous mediators as biomarkers of disease.....	41
Autoantibodies as biomarkers of autoimmune diseases.....	42
Comparison of various types of biomarkers	42
Biomarkers and systems biology	43
Systems biology approach to biomarker identification.....	44
Relation of biomarkers to other technologies and healthcare	44
Biomarkers and translational medicine.....	45
Role of biomarkers in monitoring of diseases	46
Limitations of use of biomarkers in healthcare	46
2. Technologies for Discovery of Biomarkers	47
Introduction	47
The ideal biomarker	47
Genomic technologies.....	47
Gene expression	47
<i>Whole genome expression array</i>	<i>48</i>
<i>Gene expression profiling on whole blood samples</i>	<i>49</i>
<i>Profiling gene expression patterns of white blood cells.....</i>	<i>49</i>
Tissue microarrays for study of biomarkers	49
Technologies for detection of miRNAs as biomarkers	50
Microarrays for analysis of miRNA gene expression	50
<i>Microarrays vs quantitative PCR for measuring miRNAs.....</i>	<i>51</i>
Point-of-care detection of circulating miRNAs as biomarkers.....	51
Epigenomic technologies	51
Discovery of methylation biomarkers.....	52
Proteomic technologies	53
2D GE	54
ProteoCarta® integrated proteomics discovery platform	54
Isotope-coded affinity tags.....	55
Liquid chromatography-MS/MS	55
Lucid Proteomics System	56
Magnetics beads for protein biomarker discovery	56

MASStermind™	56
Combined analysis of protein and nucleic-acid biomarkers	57
Mass spectrometry	57
2D PAGE and mass spectrometry	58
Imaging mass spectrometry	58
MALDI mass spectrometry for biomarker discovery	59
Quantitative tandem MS	59
Single-molecule mass spectrometry using a nanopore	60
Requirements for MS-based proteomic biomarker development	60
Nucleic Acid Programmable Protein Array	60
Protein tomography	61
Protein biochips/microarrays and biomarkers	61
Antibody array/affinity proteomics-based biomarker discovery	61
Detection of biomarkers using peptide array technology	63
ProtoArray®	63
Protein nanobiochip	63
Gene expression microarray data as a source of protein biomarkers	64
Quantification of protein biomarkers	64
CyTOF for quantification of biomarkers	64
Digital protein biomarker measurement	65
Multiple reaction monitoring assays	65
Real-time PCR for quantification of protein biomarkers	65
Search for biomarkers in body fluids	66
Challenges and strategies for discovery of protein biomarkers in plasma	66
Technologies for removal of highly abundant proteins in blood	66
3D structure of CD38 as a biomarker	67
BD™ Free Flow Electrophoresis System	68
Isotope tags for relative and absolute quantification	68
Plasma protein microparticles as biomarkers	68
Proteome partitioning	69
Stable isotope tagging methods	69
Technology to measure both the identity and size of the biomarker	70
Selected reaction monitoring MS	70
Targeted MS for verification of biomarkers	71
Biomarkers in the urinary proteome	72
Peptides as biomarkers of disease	72
Analysis of peptides in bodily fluids	72
Antibody biomarker discovery via evolution of peptides	73
Selected reaction monitoring for validating peptide biomarkers	74
Serum peptidome patterns	74
StSCAPA method for quantitating proteins and peptides in plasma	74
Comparison of proteomic profiling technologies for discovery of biomarkers	75
Verification for interlaboratory reproducibility of protein biomarkers	75
Significance of similar protein biomarkers in different tissues	75
Glycomic technologies	76
Cellular glycomics for discovery of cellular biomarkers	77
Metabolomic technologies	77
Genome-wide association studies for identification of metabolic biomarkers	78
Genetic influences on human blood metabolites	78
Lipid profiling	78
Mass spectrometry for discovery of metabolic biomarkers in plasma	79
Role of metabolomics in biomarker identification and pattern recognition	79
Urinary profiling by capillary electrophoresis	79
Validation of biomarkers in large-scale human metabolomics studies	80
Lipidomics	80
Disease biomarkers in breath	81
Portable breath test for volatile organic compounds	81
Detection of breath biomarkers by sensation technology	81
Detection of breath biomarkers by nanosensors	82
Detection of breath biomarkers optical frequency comb spectroscopy	82
Detection of breath biomarkers by infrared absorption spectroscopy	82
Detection of biomarkers by electronic nose	82
Fluorescent indicators for biomarkers	83
Molecular imaging technologies	83
Computer tomography	83
Magnetic resonance imaging	84
Positron emission tomography	84
Advantages of imaging biomarkers	84
Monitoring in vivo gene expression by molecular imaging	85
Molecular imaging in vivo as a biomarker	85
Challenges and future of molecular imaging	86

<i>Basic research in molecular imaging</i>	86
<i>Imaging intracellular NADH as a biomarker of disease</i>	86
<i>Devices for molecular imaging</i>	87
<i>Imaging biomarkers in clinical trials</i>	87
<i>Molecular imaging in clinical practice</i>	87
Nuclear magnetic resonance	87
Chemical derivatization to enhance biomarker detection by NMR	88
Fluxomics by using NMR	88
Nanobiotechnology	88
Dip Pen Nanolithography	89
Nanomaterials for biolabeling	89
<i>Quantum dot molecular labels</i>	90
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i>	91
<i>Magnetic nanotags for multiply detection of biomarkers</i>	91
Nanoparticles for molecular imaging	91
Nanoparticles for discovering biomarkers	92
Nanoproteomics and biomarkers	92
<i>High-field asymmetric waveform ion mobility mass spectrometry</i>	92
Nanosensors for measuring biomarkers in blood	93
Nanobiochip sensor technique for analysis of oral cancer biomarkers	93
Future prospects of application of nanobiotechnology for biomarkers	93
Bioinformatics	94
Biomarker Workflow Guide	94
Analysis of microarray data for selecting useful biomarkers	94
Role of bioinformatics in discovery of protein biomarkers	94
Role of bioinformatics in detection of cancer biomarkers	95
Biomarker databases	95
Gene networks as biomarkers	96
Role of bioinformatics in integrating various data and biomarker discovery	96
Evaluation of biomarker studies	97
3. Biomarkers and Molecular Diagnostics	99
Introduction	99
Molecular diagnostic technologies	99
Polymerase chain reaction	99
<i>Amplification</i>	99
<i>Target selection</i>	100
<i>Detection of amplified DNA</i>	100
<i>Limitations of PCR</i>	100
Real-time PCR systems	101
<i>Limitations of real-time PCR</i>	101
<i>Future applications of real-time qPCR</i>	102
<i>Real-time qPCR for quantification of circulating mtDNA</i>	102
Combined PCR-ELISA	102
Non-PCR methods	103
<i>Linked Linear Amplification</i>	103
Transcription mediated amplification	103
Rapid analysis of gene expression	103
WAVE nucleic acid fragment analysis system	104
DNA probes with conjugated minor groove binder	104
Rolling circle amplification technology	105
<i>Gene-based diagnostics through RCAT</i>	105
<i>RCAT-immunodiagnosics</i>	106
<i>RCAT-biochips</i>	106
<i>RCAT-pharmacogenomics</i>	106
Circle-to-circle amplification	106
Biomarkers and high throughput molecular screening	107
Detection and expression profiling of miRNA	107
Real-time PCR for expression profiling of miRNAs	107
Use of LNA to explore miRNA	108
Microarrays for analysis of miRNA gene expression	108
Devices for biomarkers	108
Biochips and microarrays	108
<i>Applications of biochips/microarrays</i>	109
<i>Role of biochip/microarrays in discovery of biomarkers</i>	109
Biosensors for biomarkers	110
<i>Biosensor for analysis of sweat biomarkers</i>	110
4. Biomarkers for Drug Discovery & Development	113
Introduction	113
Biomarker technologies for drug discovery	113

Proteomics-based biomarkers for drug discovery	113
Chemoproteomics	114
<i>Activity-based chemical proteomics</i>	114
Transcriptomics for drug discovery	114
Metabolomics for drug discovery	115
Biomarkers and drug safety	115
Biomarkers of adverse drug reactions	115
Applications of biomarkers in drug safety studies	116
Genomic technologies for toxicology biomarkers	116
Proteomic technologies for toxicology biomarkers	117
Metabonomic technologies for toxicology biomarkers	117
Integration of genomic and metabonomic data to develop toxicity biomarkers	117
Toxicology studies based on biomarkers	118
<i>Biomarker of genotoxicity</i>	119
<i>Biomarkers of hepatotoxicity</i>	119
<i>Biomarkers of nephrotoxicity</i>	120
<i>Cardiotoxicity</i>	122
<i>Neurotoxicity</i>	122
Applications of biomarkers for drug development	123
Application of metabolomics/metabolomics for drug development	123
Application of biomarkers by the pharmaceutical companies	124
Biomarkers in clinical trials	125
<i>NIH recommendations on the use of biomarkers in clinical trials</i>	125
<i>Advantages of biomarkers for drug development</i>	127
<i>Limitations and problems with use of biomarkers in clinical trials</i>	127
Development of static and dynamic biomarkers	128
Molecular imaging as a biomarker in drug development	128
<i>Molecular imaging in preclinical studies</i>	128
<i>Molecular imaging in clinical trials</i>	129
<i>Prospects of molecular imaging in drug discovery and development</i>	130
Pharmacogenomic biomarker information in drug labels	130
Role of biomarkers in vaccine development	131
Role of biomarkers in relation to stage of drug discovery and development	131
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development	132
Role of biomarkers for drug development in cardiovascular disorders	133
Role of biomarkers for drug development in neurological disorders	133
Significance of biomarkers in drug development	133
Organizations & resources for biomarker-based drug development	134
Biomarker Alliance	134
Biomarkers Consortium	134
Molecular Libraries and Imaging Roadmap of NIH	135
Rare Diseases Clinical Research Consortia	136
Future of biomarker-based drug development	136
5. Role of Biomarkers in Healthcare	139
Introduction	139
Biomarkers of inflammation	140
ESR and CRP as biomarkers of inflammation	140
Metabolic biomarkers of inflammation	141
YKL-40 as a biomarker inflammation and predictor of mortality	141
Biomarkers of allergic disorders	141
Biomarkers of oxidative stress	142
1,4-dihydroxynonane-mercapturic acid	142
Oxidized phospholipids	142
Oxidative DNA damage	143
Proteins as biomarkers of oxidative stress in diseases	143
Testing for oxidative stress	143
Biomarkers of hypoxia	144
Pathophysiology of hypoxia	144
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation	144
Identification of hypoxia biomarkers from exhaled breath	144
Metabolic biomarkers of hypoxia	145
Biomarkers of liver disease	145
Breath biomarkers of liver disease	145
Biomarkers of liver injury	145
Fibrosis and cirrhosis of liver	146
FibroMax	146
Hepatic encephalopathy	146
miRNA biomarkers of liver disease	147
Viral hepatitis B and C	147
<i>Biomarkers of hepatitis C</i>	147

<i>Biomarkers of hepatitis B</i>	148
Biomarkers of pancreatitis	148
Biomarkers of renal disease	149
Biomarkers of lupus nephritis	149
Biomarkers of diabetic nephropathy	150
Cystatin C as biomarker of glomerular filtration rate (GFR)	150
Estimated GFR and albuminuria as biomarkers of chronic kidney disease	150
Proteomic biomarkers of acute kidney injury	151
Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs	151
Troponin-T as a biomarker for predicting end-stage renal disease	151
Biomarkers in pediatrics	151
Pediatric critical care	151
Biomarkers of acute kidney injury in children	152
Biomarkers of miscellaneous disorders	152
Biomarkers of acid-base disorders in acute care setting	152
Biomarkers of carbon monoxide poisoning	152
Biomarkers of Castleman disease	153
Biomarkers of erectile dysfunction	153
Biomarkers of fever	154
Biomarkers of heat stroke	154
Biomarkers of hyponatremia	154
Biomarkers of inflammatory bowel disease	155
Biomarkers of radiation injury	156
Biomarkers for prediction of all-cause mortality	156
Biomarkers common to multiple diseases	156
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy	157
Biomarkers of gene-environmental interactions in human disease	158
Application of biomarkers in animal health	158
6. Biomarkers in Metabolic Disorders	161
Biomarkers of acute intermittent porphyria	161
Liver X receptors	161
Biomarkers of diabetes mellitus	161
<i>β-cell function as biomarker of diabetes</i>	163
<i>Biomarkers of hyperglycemia</i>	163
<i>Biomarkers of diabetes-associated oxidative stress</i>	163
<i>Biomarkers of inflammation associated with diabetes</i>	163
<i>Biomarkers of renal complications in diabetes mellitus type 2</i>	164
<i>Biomarkers of diabetes</i>	164
<i>Biomarkers of prediabetes</i>	164
<i>Biomarkers of insulin resistance</i>	164
<i>Elevated plasma furin level</i>	165
<i>Glycosylated hemoglobin in diabetes mellitus</i>	165
<i>Glycated albumin as a biomarker of diabetes mellitus</i>	165
<i>Low C-peptide as a biomarker of complications of diabetes type 1</i>	166
<i>Personalized management of diabetes mellitus based on biomarkers</i>	166
Biomarkers of metabolic syndrome	166
<i>Adiponectin</i>	167
<i>Cystatin C</i>	167
<i>Human plasma lipidome</i>	167
<i>Neurotensin as biomarker of obesity</i>	168
7. Biomarkers in Immune Disorders	171
Introduction	171
Biomarkers relevant to organ transplantation	171
Biomarkers of graft versus host disease	171
Biomarkers of renal allograft failure	172
Biomarkers of renal transplant tolerance	173
Biomarkers of lung transplant rejection	174
Biomarkers of GVHD following transplantation of hematopoietic cells	174
Plasma biomarkers of response to therapy of GVHD	174
Systemic lupus erythematosus	175
Adiponectin as biomarker of SLE	175
Current management and need for biomarkers of SLE	175
Role of collaborative efforts and databases of SLE biomarkers	176
C4d-bearing reticulocytes	176
CB-CAPS	176
Epigenetic biomarkers of SLE	176
Genetic loci of SLE	177
HMGB1	177
Biomarkers of systemic sclerosis	177

Biomarkers of Sjögren syndrome.....	178
8. Biomarkers of Musculoskeletal Disorders	181
Introduction	181
Muscle disorders.....	181
Biomarkers of muscle fatigue during exercise	181
Biomarkers of mitochondrial content in skeletal muscle	181
Idiopathic inflammatory myopathies.....	182
Rheumatoid arthritis.....	182
Assays for biomarkers of RA.....	183
Biomarkers for personalizing therapy of rheumatoid arthritis	183
Circulating cytokines in RA	184
Epigenetic biomarkers of rheumatoid arthritis.....	184
miRNA biomarkers in RA	184
Serum CRP in RA	185
Biomarkers of spondylarthritis	185
Biomarkers of axial spondyloarthritis	186
Biomarkers of psoriatic arthritis	186
Osteoarthritis	186
Molecular pathophysiology of OA	187
Biomarkers of osteoarthritis	187
Assays for biomarkers of OA.....	188
Biomarkers of OA.....	188
Concluding remarks and future prospects of biomarkers of OA.....	189
Biomarkers of osteoporosis	189
Assays for detection of biomarkers of osteoporosis.....	189
Bone imaging with quantitative CT and MRI	190
Circulating miRNAs as biomarkers of osteoporosis.....	190
Dual x-ray absorptiometry	191
Utility of biomarkers of osteoporosis.....	191
Biomarkers of osteonecrosis.....	191
Osteonecrosis in Gaucher's disease	191
9. Biomarkers of Infectious Diseases.....	193
Introduction	193
Technologies for discovery of biomarkers of infection	193
Chemokines as biomarkers of infection	193
Endotoxin as biomarker of infection.....	193
Proteomics for discovering biomarkers of infections.....	193
Soluble urokinase plasminogen activator receptor	194
Sepsis	194
Biomarkers of sepsis	195
<i>Circulating CPS-1 as biomarkers of organ damage in sepsis</i>	<i>196</i>
<i>CoQ10 level reduction in septic shock.....</i>	<i>196</i>
<i>Multibiomarker-based outcome risk stratification of septic shock.....</i>	<i>197</i>
<i>Nitric oxide as a biomarker of sepsis</i>	<i>197</i>
<i>SuPAR as a biomarker of sepsis</i>	<i>197</i>
Systemic inflammatory response syndrome.....	198
Tuberculosis	198
Conventional diagnosis of tuberculosis.....	199
Molecular diagnostics for tuberculosis.....	199
Biomarkers for tuberculosis.....	199
Biomarkers of pulmonary tuberculosis in the breath	200
Transcriptional signatures in active vs asymptomatic tuberculosis	200
Biomarkers of viral infections	200
Viral hepatitis	201
Biomarkers of SARS	203
Biomarkers of HIV.....	203
Biomarkers in parasitic infections.....	204
Role of biomarkers in malaria	204
Identification of biomarkers in Schistosomiasis infections.....	205
Diagnostic & therapeutic applications of biomarkers of infections.....	205
Biomarkers to discriminate bacterial from nonbacterial respiratory infections.....	205
Procalcitonin as a guide to antibiotic therapy in infections	205
10. Biomarkers of Genetic Disorders.....	207
Introduction	207
Biomarkers of Down's syndrome	207
Biomarkers of muscular dystrophy	207
Biomarkers of phenylketonuria.....	208
Genetic biomarkers of psoriasis.....	208

Biomarkers of lysosomal storage disorders	209
Biomarkers of Niemann-Pick disease	209
<i>Bile acids as biomarkers for the early diagnosis of NPD.....</i>	<i>209</i>
<i>Cholesterol oxidation products as biomarkers of NPD.....</i>	<i>209</i>
Biomarkers of mucopolysaccharidoses	210
<i>Proteomic technologies for biomarkers of MPS.....</i>	<i>210</i>
<i>Glycan-based biomarkers for MPS.....</i>	<i>211</i>
<i>Biomarkers of LSD.....</i>	<i>211</i>
<i>Prenatal diagnosis of LSD.....</i>	<i>211</i>
Biomarkers of Fabry's disease	212
11. Biomarkers of Aging	213
Introduction	213
Biomarkers of biological age.....	214
Gene variants as determinants of biological age.....	215
Gene expression profiles for calculating transcriptomic age	215
Biomarkers of healthy aging	215
Biomarkers of longevity.....	216
Effect of calorie restriction on biomarkers of longevity	216
Healthy aging index	216
Low serum thyroid hormone level as biomarker of longevity.....	216
Biomarkers as predictors of mortality with aging	217
Genetic biomarkers of aging.....	217
Genetic signatures of longevity	217
Metabolomic biomarkers of aging	218
Mitochondrial mutations as biomarkers of aging	218
Oxidative biomarkers of aging	218
Molecular diagnostics and biomarkers of age-related diseases.....	219
Protein biomarkers of aging	219
Carbamylated proteins as biomarkers of aging	219
Proteomic biomarkers of muscle aging.....	220
Role of humanin in age-related diseases	220
Role of bioinformatics in search for biomarkers of aging	220
Aging biomarkers in a genetically homogeneous population	220
Telomere attrition as aging biomarker.....	221
12. Nutritional Biomarkers	223
Introduction	223
Biomarkers of Nutrition for Development project	223
Biomarkers in nutritional epidemiology	223
Biomarkers of nutritional status	224
Ferritin as biomarker of nutritional status.....	224
Folate biomarkers related to nutritional health status	225
Iodine as biomarker of nutritional status	225
Zinc as a biomarker of nutritional status	226
Biomarkers of branched chain amino acid status.....	226
Biomarkers of caloric restriction.....	226
Biomarkers of malnutrition.....	226
Maternal nutrition during early pregnancy causes epigenetic changes	227
Proteomic biomarkers and nutrition	227
Vitamin deficiency as biomarker of disease	227
Vitamin A biomarkers	227
Vitamin B12 deficiency	228
Vitamin D deficiency as a biomarker of disease.....	229
Role of biomarkers in the development of personalized nutrition.....	229
13. Biomarkers of Cancer.....	231
Introduction	231
The ideal biomarker for cancer	231
Biomarkers and hallmarks of cancer	232
Single vs multiple biomarkers of cancer	232
Types of cancer biomarkers	233
miRNAs as biomarkers in cancer	233
<i>Diagnostic value of miRNA in cancer.....</i>	<i>235</i>
Biomarkers of epigenetic gene silencing in cancer	235
<i>5-hydroxymethylcytosine as a biomarker of cancer</i>	<i>236</i>
Carcinoembryonic antigen	236
Circulating cancer biomarkers.....	236
<i>Circulating tumor cells as cancer biomarkers.....</i>	<i>236</i>
<i>Circulating nucleic acids as potential biomarkers of cancer</i>	<i>237</i>
<i>Circulating exosomes and microvesicles as biomarkers of cancer</i>	<i>237</i>

<i>Circulating miRNAs for cancer detection</i>	238
DNA repair biomarkers	238
HER3 as biomarker of cancer.....	238
Immunologic and inflammation biomarkers of cancer	238
Metastatic cancer biomarkers	239
Molecular diagnostic techniques for cancer	239
Technologies for detection of cancer biomarkers.....	241
Genomic technologies for cancer biomarkers	241
<i>Biomarkers of PTEN tumor suppressor gene status</i>	241
<i>Cold-PCR</i>	241
<i>ddPCR for detection of cancer biomarkers in cell free plasma DNA</i>	242
<i>Digital karyotyping for cancer biomarkers</i>	242
<i>Genome analysis at the molecular level</i>	242
<i>KRAS as a biomarker of cancer</i>	243
<i>LigAmp for detection of gene mutations in cancer</i>	243
<i>Mitochondrial DNA as a cancer biomarker</i>	243
<i>Next generation sequencing for detection of cancer biomarkers</i>	244
<i>Telomerase as a biomarker of cancer</i>	245
Tissue microarrays for study of cancer biomarkers	245
Molecular fingerprinting of cancer	246
Proteomic technologies for detecting biomarkers of cancer	246
2D PAGE	247
<i>Antibody-based detection of protein biomarkers</i>	247
<i>Aptamer-based molecular probes for cancer biomarker discovery</i>	248
<i>Biomarkers of protein-drug interactions in cancer</i>	248
<i>Cancer immunomics to identify autoantibody signatures</i>	249
<i>Desorption electrospray ionization for detection of cancer biomarkers</i>	249
<i>Detection of circulating nucleosomes in serum of cancer patients</i>	249
<i>Detection of tumor biomarkers with ProteinChip technology</i>	250
<i>Glycoprotein biomarkers of cancer</i>	250
<i>HER-2/neu oncoprotein as biomarkers for cancer</i>	250
<i>Humoral proteomics</i>	251
<i>Laser capture microdissection</i>	251
<i>Membrane-type serine protease-1</i>	251
<i>Proteomic analysis of cancer cell mitochondria</i>	252
<i>Proteomic technologies for detection of autoimmune biomarkers</i>	252
SELDI-TOF MS.....	253
<i>Serum proteome analysis for early detection of cancer</i>	253
<i>Synthetic biomarker-based POC diagnostic for cancer</i>	253
<i>Triple-quadrupole MS for detection of mutant proteins</i>	253
<i>Targeted MS for validation of cancer biomarkers in plasma</i>	254
<i>Tissue proteomics for discovery of cancer biomarkers</i>	254
<i>VeraTag system for cancer biomarkers</i>	254
Metabolomic biomarkers of cancer	254
<i>Magnetic resonance for detecting metabolomics biomarkers of cancer</i>	255
<i>Choline phospholipid biomarkers of cancer</i>	255
<i>Hypoxia-inducible factor-1</i>	255
<i>Detection of drug resistance in cancer by metabolic profiling</i>	256
<i>Plasma free amino acids profiling in cancer</i>	256
<i>Urinary metabolomic biomarkers of cancer</i>	257
Epitomics for the early detection of cancer	257
Epigenetic biomarkers of cancer	257
<i>Detection of biomarkers of DNA methylation</i>	258
<i>Epigenomics Marker Machine for DNA methylation biomarkers</i>	259
<i>Histone deacetylase</i>	259
<i>MDScan™ microarray technology</i>	259
<i>Mucins as epigenetic biomarkers in epithelial cancers</i>	260
<i>PCR with bisulfite for detecting DNA methylation biomarkers in cancer</i>	260
<i>Detection of methylated DNA in serum and urine</i>	261
<i>Integrated platform for genetic and epigenetic analysis</i>	261
Nanobiotechnology for early detection of cancer to improve treatment	262
<i>Aptasensor for electrochemical detection of exosomes</i>	262
<i>Nanovesicles for detection of cancer biomarkers</i>	262
<i>Nanowire biosensors for detection of cancer biomarkers</i>	263
<i>NP-peptide complexes for detection of cancer biomarkers in urine</i>	264
Ultrasound radiation to enhance release of a tumor biomarker	264
In vivo imaging of cancer biomarkers	264
<i>Computer tomography</i>	264
<i>Optical systems for in vivo molecular imaging of cancer</i>	265
<i>Positron emission tomography</i>	265
<i>Imaging of tumor oxygenation and microvascular permeability by MRI</i>	265

<i>Xenon-enhanced MRI</i>	266
Kallikrein gene family and cancer biomarkers	266
Detection of CTCs as biomarkers of cancer	266
Applications of cancer biomarkers	267
Use of biomarkers for cancer classification	267
<i>Cancer classification using microarrays</i>	267
<i>Proteomic classification of cancer</i>	268
Use of biomarkers for early detection of cancer	268
Applications of biomarkers for cancer diagnosis	268
<i>Methylated DNA sequences as cancer biomarkers</i>	268
<i>MicroRNA expression profiling for diagnosis of human cancers</i>	269
<i>MUC4 as a diagnostic biomarker in cancer</i>	270
Applications of biomarkers for cancer diagnosis and therapy	270
<i>ARTS as a biomarker as well as a basis of anticancer drugs</i>	271
<i>Asparagine synthetase as biomarker for therapy with L-asparaginase</i>	272
<i>Peptide-based agents for targeting cancer biomarkers</i>	272
<i>PI3K mutations as a biomarker for use as a companion diagnostic</i>	272
Biomarkers for assessing efficacy of cancer therapy	273
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy</i>	273
<i>P53 expression level as biomarker of efficacy of cancer gene therapy</i>	273
Biomarkers of angiogenesis for developing antiangiogenic therapy	273
<i>Biomarkers of response to antiangiogenic agents</i>	273
<i>Circulating endothelial cells as targets for antiangiogenic drugs</i>	274
<i>Imaging biomarkers for evaluation of antiangiogenic agents</i>	274
<i>Tumor endothelial biomarkers</i>	275
<i>VEGF signaling inhibitors as biomarkers</i>	275
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor</i>	275
Biomarkers of prognosis in cancer treatment	276
Biomarkers for monitoring cancer therapy	276
Biomarkers of drug resistance in cancer	276
<i>A systems approach to biomarkers of innate drug resistance</i>	277
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance</i>	277
<i>Methylation biomarkers of drug resistance in cancer</i>	277
<i>STAT3 and resistance to cisplatin</i>	278
Biomarkers of radiation therapy for cancer	278
Role of biomarkers in drug development in oncology	278
Biomarker-based approval of an anticancer drug regardless of site	279
Biomarkers in plucked hair for assessing cancer therapy	280
Met receptors as targets for anticancer drugs	280
Molecular imaging of tumor as a guide to drug development	280
<i>Use of PET and SPECT to assess response to anticancer drugs</i>	281
<i>Use of MRI to assess response to anticancer drugs</i>	281
Role of biomarkers in phase I clinical trials of anticancer drugs	282
Safety biomarkers in oncology studies	282
Biomarkers according to organ/type of cancer	282
Bladder cancer biomarkers	283
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer</i>	283
<i>NMP22 BladderChek</i>	283
<i>Urinary telomerase as biomarker for detection of bladder cancer</i>	283
<i>Concluding remarks about biomarkers of urinary cancer</i>	283
Brain tumor biomarkers	284
<i>14-3-3zeta expression as prognostic biomarker for glioblastoma</i>	284
<i>ALDH1A3 as a biomarker of glioblastoma</i>	285
<i>Biomarkers to predict response to EGFR inhibitors</i>	285
<i>Biomarkers for predicting recurrence of meningiomas</i>	285
<i>CD133 as biomarker of resistance to radiotherapy</i>	285
<i>Circulating microvesicles as biomarkers</i>	286
<i>CSF attractin as a biomarker of malignant astrocytoma</i>	286
<i>ELTD1 as a biomarker of gliomas</i>	286
<i>Methylation profiling of brain tumors</i>	286
<i>Metabolite biomarkers of brain tumors</i>	288
<i>miRNAs as biomarkers of brain tumors</i>	288
<i>MRI biomarker for response of brain tumor to therapy</i>	289
<i>Multigene predictor of outcome in glioblastoma</i>	289
<i>Neuroimaging biomarkers combined with DNA microarray analysis</i>	289
<i>Proteomic analysis of CSF for identification of biomarkers for gliomas</i>	290
<i>Receptor protein tyrosine phosphatase β as biomarker of gliomas</i>	290
<i>Serum protein fingerprinting</i>	290
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors</i>	290
<i>Future prospects of biomarkers of malignant gliomas</i>	290
Bone tumor biomarkers	291

<i>Cytogenetics for the study of bone and soft tissue tumors</i>	291
<i>Biomarkers of Ewing's tumors</i>	291
<i>Role of biomarkers in the diagnosis of bone tumors</i>	292
Breast cancer biomarkers	292
<i>Autoantibody biomarkers of breast cancer</i>	293
<i>Biomarkers of breast cancer in breath</i>	294
<i>Biomarkers for breast cancer in nipple aspiration fluid</i>	294
<i>Circulating tumor DNA as biomarker of breast cancer</i>	294
<i>Circulating exosomes as biomarkers of breast cancer</i>	295
<i>Proteomic biomarkers of breast cancer</i>	295
<i>Quantification of biomarker expression patterns by flow cytometry</i>	295
<i>Quantitative realtime PCR assays for biomarker validation</i>	296
<i>Cdk6 as a biomarker of breast cancer</i>	296
<i>Centromere protein-F</i>	296
<i>Carbonic anhydrase IX</i>	297
<i>COX-2 as a biomarker of breast cancer</i>	297
<i>G88 as a biomarker of progression of ER+ breast cancer</i>	297
<i>Glycomic biomarkers of breast cancer</i>	297
<i>HER-2/neu oncoprotein</i>	298
<i>High mobility group protein A2</i>	299
<i>Hypermethylated genes as biomarkers of metastatic breast cancer</i>	299
<i>Lipocalin 2 as biomarker of breast cancer progression</i>	300
<i>Long intervening non-coding RNAs</i>	300
<i>Mammaglobin</i>	300
<i>miRNA biomarkers of breast cancer</i>	300
<i>p27 expression as biomarker for survival after chemotherapy</i>	301
<i>Podocalyxin</i>	302
<i>Proneurotensin and Proenkephalin</i>	302
<i>Proliferating cell nuclear antigen</i>	302
<i>Protein kinase C as a predictive biomarker of metastatic breast cancer</i>	302
<i>Retinoblastoma tumor suppressor gene as a biomarker</i>	303
<i>Riboflavin carrier protein</i>	303
<i>Risk of invasive cancer after diagnosis of ductal carcinoma in situ</i>	303
<i>Serum CA 15-3 as biomarker of prognosis in advanced breast cancer</i>	304
<i>Stage-specific embryonic antigen-3</i>	304
<i>Suppressor of deltex protein</i>	304
<i>Tumor microenvironment as biomarker of metastasis in breast cancer</i>	304
<i>Type III TGF-β receptor as regulator of cancer progression</i>	305
<i>Diagnostic tests based on breast cancer genes</i>	305
<i>Prognostic role of breast cancer genes</i>	306
<i>Protein biomarkers for breast cancer prevention</i>	307
<i>Biomarkers to evaluate efficacy of chemoprevention</i>	307
<i>Biomarkers of response to chemotherapy of breast cancer</i>	307
<i>Biomarker-guided decisions for breast cancer therapy</i>	308
<i>Concluding remarks and future prospects of breast cancer biomarkers</i>	308
Cervical cancer biomarkers	308
Gastrointestinal cancer biomarkers	309
<i>Esophageal cancer biomarkers</i>	310
<i>Gastric cancer biomarkers</i>	310
<i>Colorectal cancer biomarkers</i>	311
Head and neck cancer	317
Leukemia biomarkers	319
<i>Chromosome translocations in leukemias</i>	319
<i>DNA methylation biomarkers in leukemia</i>	319
<i>Gene mutations as biomarkers in leukemia</i>	320
<i>Molecular diagnostic techniques for leukemia</i>	320
<i>Proteomic technologies for discovering biomarkers of leukemia</i>	321
<i>Biomarkers of chronic lymphocytic leukemia</i>	321
<i>Biomarkers of chronic myeloid leukemia</i>	322
<i>Biomarkers of drug resistance in leukemia</i>	322
<i>Biomarkers of myelodysplastic syndromes</i>	322
Lymphoma biomarkers	323
Liver cancer biomarkers.....	323
<i>Biomarkers indicating lower risk of HCC in coffee drinkers</i>	324
<i>Metabonomic profiles discriminate HCC from liver cirrhosis</i>	324
<i>Urinary biomarkers of HCC</i>	324
Lung cancer biomarkers.....	325
<i>Autoantibodies as biomarkers in lung cancer</i>	326
<i>Biomarkers associated with neuroendocrine differentiation in NSCLC</i>	326
<i>Biomarkers of chronic inflammation in lung cancer</i>	327
<i>Biomarkers for predicting sensitivity to chemotherapy in lung cancer</i>	327

<i>Biomarkers for prediction of sensitivity to EGFR inhibitors</i>	328
<i>CTCs as biomarkers of lung cancer</i>	329
<i>Genomic biomarkers of lung cancer</i>	329
<i>Methylation biomarkers of lung cancer</i>	330
<i>miRNA biomarkers in lung cancer</i>	330
<i>Noninvasive detection of lung cancer using exhaled breath</i>	331
<i>Serum protein biomarkers of lung cancer</i>	331
<i>tNOX as biomarker of lung cancer</i>	332
<i>Tumor-derived DNA and RNA markers in blood</i>	332
<i>Volatile organic compounds in the exhaled breath</i>	333
Malignant pleural mesothelioma	333
Melanoma biomarkers	334
Nasopharyngeal carcinoma biomarkers	335
<i>Proteomic biomarkers of nasopharyngeal cancer</i>	336
<i>miRNA biomarkers of nasopharyngeal carcinoma</i>	336
Oral cancer biomarkers	337
Ovarian cancer biomarkers	337
<i>3D microfluidic platform to assess multiple ovarian cancer biomarkers</i>	338
<i>CA125 as biomarker of ovarian cancer</i>	338
<i>Epitomics approach for ovarian cancer biomarkers in serum</i>	339
<i>FGF18 as a biomarker in ovarian cancer</i>	339
<i>Gene expression studies in ovarian cancer</i>	339
<i>HE4 protein in urine as a biomarker for ovarian cancer</i>	340
<i>Hematogenous metastasis of ovarian cancer</i>	340
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i>	340
<i>Mutation of genes in ovarian cancer</i>	341
<i>Serum biomarkers of ovarian cancer prognosis</i>	341
<i>TIM-3 as a biomarker of ovarian cancer</i>	341
<i>Multiplex assays for biomarkers of ovarian cancer</i>	342
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i>	342
Pancreatic cancer biomarkers	343
<i>Discovery and validation of pancreatic cancer biomarkers</i>	344
<i>Cancer stem cells as biomarkers of pancreatic cancer</i>	344
<i>Circulating exosomes as biomarkers of pancreatic cancer</i>	344
<i>Histone modifications used as biomarkers in pancreatic cancer</i>	344
<i>miRNA biomarkers of pancreatic cancer</i>	345
<i>Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer</i>	346
<i>Proteomic biomarkers of pancreatic cancer</i>	346
<i>Concluding remarks on biomarkers of pancreatic cancer</i>	346
Parathyroid cancer biomarkers	347
Peripheral nerve tumors	347
<i>Biomarkers of neurofibromatosis</i>	347
Prostate cancer	348
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i>	348
<i>B7-H3 as biomarker of prostate cancer</i>	349
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i>	349
<i>Detection of prostate cancer biomarkers in urine</i>	349
<i>Detection of prostatic intraepithelial neoplasia</i>	350
<i>Epigenetic biomarkers of prostate cancer</i>	350
<i>Exosomes as biomarkers of prostate cancer</i>	351
<i>Gene expression analysis of prostate cancer</i>	351
<i>Genetic biomarkers of prostate cancer</i>	352
<i>Identification of prostate cancer mRNA biomarkers</i>	352
<i>Kallikreins as biomarkers of prostate cancer</i>	353
<i>LCM for diagnosis of prostate cancer</i>	353
<i>Microarray for diagnosis of prostate cancer</i>	354
<i>miRNA biomarkers of prostate cancer</i>	354
<i>Prostate cancer biomarkers in semen</i>	355
<i>PSA as biomarker of prostate cancer</i>	355
<i>ProPSA as biomarker of prostate cancer</i>	356
<i>Prostate Health Index</i>	356
<i>Prostasomes in blood as biomarker of prostate cancer</i>	356
<i>PSMA as biomarker of prostate cancer</i>	357
<i>Sarcosine as a metabolic biomarker of prostate cancer</i>	357
<i>Silenced CDH13 gene as a biomarker of cancer</i>	357
<i>Serum-protein fingerprinting</i>	357
<i>Concluding remarks on biomarkers of prostate cancer</i>	358
Renal cancer biomarkers	358
<i>Gene expression profile of RCC for biomarkers</i>	358
<i>miRNA biomarkers of renal cancer</i>	359
<i>Use of proteomics for detection of RCC biomarkers</i>	359

<i>Use of RCC biomarkers for prognosis and therapy</i>	359
Thyroid cancer biomarkers	360
<i>Detection of BRAF mutation</i>	360
<i>Gene expression biomarkers of thyroid cancer</i>	361
<i>miRNA biomarkers of thyroid cancer</i>	361
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer</i>	361
Role of the NCI in cancer biomarkers	362
Future prospects for cancer biomarkers	363
Cancer biomarker research at academic institutions	363
Future challenges in the discovery of cancer biomarkers	363
14. Biomarkers of Disorders of the Nervous System	365
Introduction	365
Discovery of biomarkers for neurological disorders	365
Antibodies as biomarkers in disorders of the nervous system	366
Biomarker identification in the CSF using proteomics	367
Biomarker identification in the CSF using lipidomics	367
Cerebral microdialysis for the study of biomarkers of cerebral metabolism	367
Brain imaging for detection of biomarkers	368
Data mining for biomarkers of neurological disorders	368
Detection of protein biomarkers of CNS disorders in the blood	369
Genomic technologies for study of biomarkers of neurological disorders.....	369
Biomarkers of neuroinflammation	369
Biomarkers of neural regeneration	370
Biomarkers of disruption of blood-brain barrier.....	370
Biomarkers of neurotoxicity.....	371
Glial fibrillary acidic protein as biomarker of neurotoxicity	371
Single-stranded DNA as a biomarker of neuronal apoptosis	372
Biomarkers of neurogenetic disorders	372
Charcot-Marie Tooth disease	372
Duchenne and Becker muscular dystrophy	373
Early-onset torsion dystonia	374
Fragile X syndrome	374
Genetic neurotransmitter disorders	375
Hereditary neuropathy with liability to pressure palsies.....	375
Hereditary metabolic storage disorders with neurologic manifestations	375
<i>Gaucher disease</i>	375
<i>Pompe's disease</i>	376
Mitochondrial disorders affecting the nervous system	376
Spinal muscular atrophy	376
<i>Biomarkers of SMA</i>	377
Biomarkers of the aging brain	377
Cellular biomarker of aging of the brain	377
CSF F2-isoprostanes as biomarker of aging brain	377
IL-6 as a biomarker of cognitive impairment with aging	378
MRI transverse relaxation rate alteration as biomarker of aging brain.....	378
Protein aggregation as a biomarker of aging brain.....	378
Telomere shortening as a biomarker of aging brain and dementia	378
Biomarkers of neurodegenerative disorders	379
Biomarkers of dementia.....	379
Biomarkers of vascular dementia	380
Biomarkers of Alzheimer's disease	380
The ideal biomarker for AD.....	382
Methods for determining biomarkers of AD.....	382
<i>Gene expression patterns in AD</i>	382
<i>Magnetic resonance spectroscopy in AD</i>	383
<i>MicroRNAs as biomarkers of neurodegenerative disorders</i>	383
<i>MRI for biomarkers of AD</i>	384
<i>Nanotechnology to measure Aβ-derived diffusible ligands</i>	385
<i>PET scanning for biomarkers of AD</i>	385
<i>Simultaneous measurement of several biomarkers for AD</i>	387
<i>Targeting of chemokine receptor as biomarker for brain imaging</i>	387
Biomarkers of AD in CSF	388
<i>CSF sulfatide as a biomarker for AD</i>	388
<i>CSF Reelin as biomarker of AD</i>	388
<i>Monitoring of synthesis and clearance rates of Aβ in the CSF</i>	388
<i>Protein biomarkers of AD in CSF</i>	389
<i>Tau proteins in CSF</i>	390
<i>Tests for the detection of Aβ in CSF</i>	390
<i>Tests combining CSF tau and Aβ</i>	391
Blood biomarkers of AD	392

<i>A serum protein-based algorithm for the detection of AD</i>	392
<i>Amyloid precursor protein</i>	392
<i>Detection of aggregated misfolded proteins in the blood</i>	392
<i>Lipid biomarkers for preclinical detection of AD</i>	393
<i>Lymphocyte Proliferation Test</i>	393
<i>Metabolomic biomarker profiling</i>	393
<i>Plasma protein biomarkers of AD</i>	393
<i>Protein kinase C in red blood cells</i>	394
Urinary biomarkers of AD	395
A biomarker-based skin test for AD	395
Salivary biomarkers of AD	395
Applications of biomarkers of AD	396
<i>Biomarker changes in autosomal dominantly inherited AD</i>	396
<i>Correlation of imaging biomarkers with CSF biomarkers of AD</i>	396
<i>Genetic tests for AD</i>	396
<i>Humanin as a biomarker as well as neuroprotective in AD</i>	397
<i>Plasma biomarkers of drug response in AD</i>	397
<i>PredictAD project</i>	398
<i>TOMM40 gene and risk of AD</i>	398
<i>Use of biomarkers to predict AD in patients with MCI</i>	398
Concluding remarks about biomarkers for AD and future prospects	399
Biomarkers of Parkinson's disease	400
Autoantibodies as biomarkers of PD	401
Biomarkers of PD based on gene expression in blood	401
Cardiac denervation as a biomarker of PD	401
Caffeine levels in blood	402
Genetic biomarkers of PD	402
Imaging biomarkers of PD	403
Metabolic brain networks as biomarkers	403
Metabonomic biomarker profile for diagnosis and monitoring of PD	404
Protein biomarkers of PD	404
<i>P11 protein as a biomarker of depression in PD</i>	404
Serum vitamin D as a biomarker of PD	405
Biomarkers of prodromal PD	405
Future needs for biomarkers of PD	405
Biomarkers of Huntington's disease	406
Genetic biomarker of HD progression	407
Quantitative MRI measurement of brain atrophy as biomarker of HD	408
Metabolic networks as biomarkers of preclinical Huntington disease	408
Biomarkers of Wilson's disease	408
Biomarkers of amyotrophic lateral sclerosis	409
ALS biomarker detection in blood vs CSF	410
Biomarkers of neuroinflammation in ALS	410
Genetic biomarkers of ALS	410
Imaging biomarkers of ALS	411
Metabolomic biomarkers of ALS	411
Proteomic biomarkers of ALS	411
Ideal biomarker of ALS	412
Future of biomarkers of ALS	412
HIV-1-associated neurocognitive disorders	412
Biomarkers of dementia in HIV-1-infected patients	413
Biomarkers of autoimmune encephalitis	413
Biomarkers of prion diseases	413
14-3-3 protein and tTau/P-Tau ratio	413
Bioluminescence imaging as a surrogate biomarker of prion infectivity	414
miRNAs as biomarkers of prion-induced neurodegeneration	414
MRI biomarker of CJD	414
Prion protein detection by real-time quaking-induced conversion	415
Prions in the urine of patients with variant CJD	415
Biomarkers of multiple sclerosis	415
Antibodies in multiple sclerosis	417
<i>Antibodies to galactocerebroside</i>	417
<i>Antibodies to myelin oligodendrocyte glycoprotein</i>	417
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS	417
Brain imaging biomarkers of multiple sclerosis	418
<i>MRI biomarkers of multiple sclerosis</i>	418
<i>Molecular imaging</i>	418
Biomarkers of response to therapy of multiple sclerosis	419
<i>Biomarkers of response to of interferon β-1a</i>	419
<i>DNA motifs in the blood as biomarkers of response to treatment</i>	419
<i>Gene expression</i>	419

<i>Lymphocyte subsets as biomarkers of therapeutic response</i>	420
<i>Neurofilaments</i>	421
<i>Vitamin D as predictor of activity and progression of MS</i>	421
CSF biomarkers in multiple sclerosis	421
CSF Cystatin C as a biomarker of multiple sclerosis	421
Detecting autoantibodies in multiple sclerosis	421
<i>Switch-associated protein 70 antibodies in multiple sclerosis</i>	422
Gelsolin as a biomarker of multiple sclerosis	422
Matrix metalloproteinases as biomarkers in multiple sclerosis	422
Oligoclonal bands as biomarkers of MS	423
Serum proteomic pattern analysis in multiple sclerosis	423
T cells as biomarkers of multiple sclerosis	423
Concluding remarks and future perspective for biomarkers of multiple sclerosis	423
Biomarkers of cerebrovascular disorders	424
Biomarkers of stroke	424
<i>Etiological biomarkers of ischemic stroke</i>	426
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i>	427
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i>	427
<i>CCL23 for prediction of stroke patient outcome</i>	427
<i>CRP as biomarker of risk of stroke</i>	427
<i>CSF biomarkers in acute stroke</i>	428
<i>Gene expression in blood following ischemic stroke</i>	428
<i>Glutathione S-Transferase-n</i>	428
<i>Intercellular adhesion molecule 1 as biomarker of ischemic stroke</i>	429
<i>Lp-PLA2 and CRP as biomarkers for stroke</i>	429
<i>Matrix metalloproteinase-9</i>	429
<i>miRNAs as biomarkers of stroke</i>	429
<i>Neuroserpin polymorphisms as a biomarker of stroke</i>	430
<i>NMDA receptors as biomarkers of excitotoxicity in stroke</i>	430
<i>Nucleosomes as biomarkers of stroke</i>	430
<i>PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke</i>	430
<i>Visinin-like protein 1</i>	431
<i>Biomarker panels for stroke</i>	431
<i>Future prospects for biomarkers of stroke</i>	431
Biomarkers of cerebral vasospasm	432
Biomarkers of intracerebral hemorrhage	432
Biomarkers of hypoxic brain damage	433
Biomarkers of ischemic brain damage	433
D-dimer as a biomarker of cerebral venous thrombosis	434
Biomarkers of traumatic brain injury	434
Technologies for identification of biomarkers of TBI	434
<i>Cerebral microdialysis for study of biomarkers of TBI</i>	434
<i>Proteomic technologies for biomarkers of TBI</i>	435
<i>Systems biology approach for discovery of biomarkers of TBI</i>	436
Biomarkers of TBI	436
<i>Aβ as a biomarker of TBI</i>	437
<i>CCL11 as a biomarker of chronic traumatic encephalopathy</i>	437
<i>Diffusion tensor imaging in TBI</i>	437
<i>Glial fibrillary acidic protein as biomarker of TBI</i>	437
<i>Hyperphosphorylated axonal neurofilament protein</i>	438
<i>IL-6 and nerve growth factor as biomarkers of TBI</i>	438
<i>Myelin basic protein</i>	438
<i>Neural exosome cargo</i>	438
<i>Neurofilament heavy chain</i>	438
<i>Serum S100β as biomarker of TBI</i>	439
<i>SNTF as a biomarker for predicting cognitive decline after mild TBI</i>	439
<i>Tau as biomarker of TBI</i>	440
<i>Ubiquitin C-terminal Hydrolase-L1</i>	440
Biomarkers of inflicted TBI in infants	441
Biomarkers of concussion	441
Clinical applications of biomarkers of TBI	441
Biomarkers of CNS infections	442
Biomarkers of bacterial meningitis	442
Biomarkers of viral infections of CNS	443
<i>Biomarkers of CNS HIV infection</i>	443
<i>CSF kynurenin acid level as a biomarker of tick-borne encephalitis</i>	443
<i>Serum uric acid levels as biomarker of acute CNS viral infections</i>	443
Biomarkers of epilepsy	444
Biochemical markers of epilepsy	444
Biomarkers of temporal lobe epilepsy	445
Biomarkers of drug-resistant epilepsy	445

Genetic epilepsies	445
Electrophysiological biomarkers of epilepsy	445
Imaging biomarkers of epilepsy	446
Protein biomarkers of inflammation in epilepsy	446
Biomarkers of normal pressure hydrocephalus	446
Biomarkers of pseudotumor cerebri.....	447
Biomarkers of retinal disorders	447
Biomarkers of age-related macular degeneration	447
Biomarkers of sleep disorders	448
Biomarker of excessive daytime sleepiness	448
Biomarkers of obstructive sleep apnea.....	449
Biomarkers of restless legs syndrome.....	449
Biomarkers of pain.....	450
Biomarkers of disorders with musculoskeletal pain	450
Biomarkers of neuropathic pain	450
Brain insular glutamate as biomarker of fibromyalgia	451
Biomarkers of visceral pain	451
Biomarkers of migraine.....	451
Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome	452
Biomarkers of psychiatric disorders.....	453
Anorexia nervosa	453
Attention-deficit hyperactivity disorder	453
Biomarkers of autism	454
<i>Epigenetics of ASD.....</i>	<i>454</i>
<i>Gastrointestinal microbiota disturbances and ASD.....</i>	<i>454</i>
<i>Genetic factors in ASD.....</i>	<i>455</i>
<i>Immune biomarkers of ASD</i>	<i>455</i>
<i>Metabolic disturbances in autism.....</i>	<i>455</i>
<i>Neurophysiological biomarkers</i>	<i>456</i>
<i>Role of oxidative stress in autism.....</i>	<i>456</i>
<i>Test for ASD based on a 55-gene expression panel</i>	<i>456</i>
<i>Umbilical cord biomarkers.....</i>	<i>457</i>
Biomarkers of bipolar disorder	457
Biomarkers of depression.....	457
<i>Biochemical biomarkers of depression</i>	<i>459</i>
<i>Biomarkers and response to antidepressant treatment</i>	<i>459</i>
<i>Cingulate cortex activity and response to antidepressants.....</i>	<i>460</i>
<i>Genetic biomarkers of response to antidepressants</i>	<i>460</i>
<i>Inflammatory biomarkers of depression and psychosis</i>	<i>460</i>
<i>P11 as a biomarker of depression</i>	<i>461</i>
<i>Panels of blood-based biomarkers for diagnosis of MDD</i>	<i>461</i>
<i>Plasma metabolomics for diagnosis of MDD.....</i>	<i>461</i>
<i>Post-partum depression.....</i>	<i>461</i>
Biomarkers of posttraumatic stress disorder	462
Biomarkers of psychosis	463
Biomarkers of schizophrenia.....	463
<i>Biomarkers of abnormalities of visual information processing</i>	<i>464</i>
<i>Genetic biomarkers of schizophrenia</i>	<i>464</i>
<i>Gene expression analysis of blood for biomarkers of schizophrenia.....</i>	<i>464</i>
<i>Metabolic biomarkers of schizophrenia.....</i>	<i>465</i>
<i>Proteomic studies for biomarkers of schizophrenia</i>	<i>465</i>
Biomarkers of suicide	465
15. Biomarkers of Cardiovascular Disorders	467
Epidemiology of cardiovascular disease.....	467
Biomarkers of cardiovascular diseases	467
Biomarkers of acute myocardial infarction.....	469
Genetic biomarkers of cardiovascular disorders.....	469
Methods for identification of cardiovascular biomarkers	471
Application of proteomics for biomarkers of cardiovascular disease	471
<i>Targeted MS-based pipeline approach</i>	<i>471</i>
<i>Cardiovascular disease biomarker panel.....</i>	<i>472</i>
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip.....	472
Metabolomic technologies for biomarkers of myocardial ischemia	472
Imaging biomarkers of cardiovascular disease	472
<i>Annexin A5 as an imaging biomarker of cardiovascular disease.....</i>	<i>473</i>
<i>Cardiovascular MRI</i>	<i>473</i>
<i>Cardiovascular hybrid imaging.....</i>	<i>473</i>
<i>Myocardial perfusion imaging</i>	<i>473</i>
Implantable magnetic biosensors for detecting cardiac biomarkers.....	474
Applications of biomarkers of cardiovascular disease.....	474

Biomarkers for ischemic heart disease and myocardial infarction	474
<i>Troponin</i>	475
<i>Natriuretic peptide</i>	476
<i>Copeptin</i>	477
<i>Creatine kinase muscle brain</i>	478
<i>miRNAs as biomarkers of acute coronary syndrome</i>	478
<i>Myoglobin</i>	478
<i>Fatty acid binding protein</i>	478
<i>Growth Differentiation Factor-15</i>	479
<i>High density lipoprotein 2</i>	479
<i>Cripto-1 as a biomarker of myocardial infarction</i>	479
<i>Cataract as a biomarker of ischemic heart disease</i>	479
<i>Plasma CD93 as a biomarker for coronary artery disease</i>	480
<i>Plasma fetuin-A levels and the risk of myocardial infarction</i>	480
<i>YKL-40 as an inflammatory biomarker in ischemic heart disease</i>	480
Biomarkers of cardiomyopathy	480
<i>miRNA biomarkers of peripartum cardiomyopathy</i>	480
<i>Takotsubo cardiomyopathy</i>	481
<i>Troponin T levels in hypertrophic cardiomyopathy</i>	481
Biomarkers of heart failure	481
<i>Annexin A5 for prognosis of heart failure</i>	481
<i>Angiogenesis biomarkers</i>	482
<i>β-2a protein as a biomarker of heart failure</i>	482
<i>Desmin</i>	482
<i>Galectin-3 as biomarker of acute heart failure</i>	482
<i>G protein-coupled receptor kinase-2 as biomarker of CHF</i>	483
<i>KIF6 gene as biomarker of heart failure</i>	483
<i>Metabolic biomarkers of heart failure</i>	484
<i>miRNA biomarkers of heart failure</i>	484
<i>Natriuretic peptide as biomarker of heart failure</i>	484
<i>Oxidative stress as biomarker of heart failure</i>	485
<i>Soluble source of tumorigenicity 2</i>	485
<i>Future prospects for biomarkers of heart failure</i>	485
Biomarkers for atherosclerosis	486
<i>9p21-3 locus and coronary atherosclerosis</i>	486
<i>Adipocyte enhancer-binding protein 1</i>	486
<i>Gene signatures on leucocytes as biomarkers of atherosclerosis</i>	486
<i>Ghrelin as a biomarker of atherosclerosis</i>	487
<i>Imaging biomarkers of hypercholesterolemia/atherosclerosis</i>	487
<i>Inflammatory biomarkers of atherosclerosis</i>	487
<i>Lipid-modified proteins as biomarkers of atherosclerosis</i>	488
<i>Lp-PLA2 as biomarker of atherosclerotic heart disease</i>	488
<i>Metabolomic profile in hypercholesterolemia</i>	488
<i>Nitric oxide impairment and atherosclerosis</i>	488
<i>Oxygen free radicals as biomarkers of atherosclerosis</i>	488
<i>Proteomic profiles of serum inflammatory biomarkers of atherosclerosis</i>	489
Biomarkers of coronary heart disease	489
<i>Apolipoproteins as risk factors for coronary heart disease</i>	489
<i>CRP as biomarker of risk for coronary heart disease</i>	490
<i>High level of blood ceramides as a biomarker of CHD</i>	490
<i>Impairment of EPCs by oxidative stress as a biomarker of disease</i>	491
<i>Role of TNF in acute coronary syndromes</i>	491
<i>Serum parathyroid hormone as biomarker of CHD</i>	491
<i>Serum stem cell factor as a biomarker of CHD</i>	491
<i>VILCAD biomarker score for prediction of long-term mortality in CHD</i>	492
Biomarkers for pulmonary arterial hypertension	492
Biomarkers of abdominal aortic aneurysm	493
Biomarkers of thrombotic disorders	494
Biomarkers of arterial thromboembolism	494
<i>Nanoparticles as synthetic biomarkers of thrombus formation</i>	494
Biomarkers of venous thromboembolism	494
<i>BNP and cTnT as biomarkers of outcome in pulmonary embolism</i>	495
<i>D-dimer as biomarker of venous thromboembolism</i>	495
<i>Molecular biomarkers of venous thromboembolism</i>	495
Genetic biomarkers for cardiovascular disease	495
<i>Biomarkers of inherited cardiomyopathies</i>	495
<i>Gene mutations in pulmonary arterial hypertension</i>	496
<i>Gene variant as a risk factor for sudden cardiac death</i>	496
<i>Genetic biomarkers of early onset myocardial infarction</i>	497
<i>Genetic biomarkers of atherosclerosis</i>	497
<i>IL-1 gene polymorphism as biomarker of cardiovascular disease</i>	497

<i>IL-6R signaling pathway and coronary heart disease</i>	497
<i>Kallikrein gene mutations in cardiovascular disease</i>	498
<i>Kallikrein gene and essential hypertension</i>	498
<i>Mutations in the low density lipoprotein receptor gene</i>	498
<i>Mutations within several genes that code for ion channel</i>	499
<i>Polymorphisms of the eNOS gene and angina pectoris</i>	499
<i>Lipoprotein (a) genetics</i>	499
<i>Polymorphisms in the apolipoprotein C gene</i>	499
<i>Polymorphisms in the apolipoprotein E gene</i>	500
<i>Polymorphism in the angiotensinogen gene</i>	500
Multiple biomarkers for prediction of death from cardiovascular disease.....	501
Role of biomarkers in the management of cardiovascular disease	501
Biomarkers in the diagnosis/prognosis of myocardial infarction.....	501
Biomarkers for prevention of cardiovascular disease.....	501
C reactive protein as biomarker of response to statin therapy.....	503
C125 as biomarker for stratification in heart disease	504
HSP72 and eNOS as biomarkers of cardioprotective effect of HBO.....	504
Multimarker panel for prognosis in chronic heart failure	504
Molecular signature analysis in management of cardiovascular diseases	505
Presage ST2 Assay.....	505
Role of circulating biomarkers and mediators of cardiovascular dysfunction.....	505
Use of protein biomarkers for monitoring acute coronary syndromes.....	505
Use of biomarkers for prognosis of recurrent atrial fibrillation	506
Use of multiple biomarkers for monitoring of cardiovascular disease.....	506
Use of biomarkers in the management of peripheral arterial disease	507
Use of biomarkers in the management of hypertension.....	507
Systems approach to cardiovascular biomarker research	507
16. Biomarkers of Pulmonary Diseases	509
Introduction	509
Association of biomarkers of inflammation with lung function in the elderly	509
Biomarkers of oxidative stress in lung diseases.....	510
Biomarkers of community-acquired pneumonia.....	510
Biomarkers of acute lung injury and respiratory distress syndrome	510
<i>Cytokine/chemokine biomarkers of SARS</i>	510
<i>Plasma biomarkers related to inflammation</i>	511
<i>Urinary NO as biomarker</i>	511
Biomarkers of interstitial lung disease	511
<i>Pulmonary surfactant proteins as biomarkers for lung diseases</i>	511
<i>Serum KL-6 as biomarker of interstitial lung disease</i>	512
Biomarkers of chronic obstructive pulmonary disease.....	512
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema</i>	512
<i>Biomarkers of extracellular matrix turnover in COPD</i>	513
<i>Biomarkers of lung failure in COPD</i>	513
<i>BNP as a biomarker of chronic pulmonary disease</i>	513
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers</i>	514
<i>C-reactive protein as a biomarker of COPD</i>	514
<i>Gene expression profile in peripheral blood of patients with COPD</i>	514
<i>Hyperuricemia as a biomarker of early mortality in COPD</i>	514
<i>Increased expression of PIGF as a biomarker of COPD</i>	514
Biomarkers of asthma	515
<i>Biomarker for rhinovirus-induced asthma exacerbation</i>	515
<i>Biomarkers for predicting response to corticosteroid therapy</i>	515
<i>Comparison of biomarkers of asthma and COPD</i>	515
<i>Cytokines as biomarkers of asthma severity</i>	516
<i>Exhaled NO as a biomarker of asthma</i>	516
<i>Endothelin-1 in exhaled breath as biomarker of asthma</i>	517
<i>IgE as guide to dosing of omalizumab for asthma</i>	517
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab</i>	517
Biomarkers of cystic fibrosis.....	518
17. Biomarkers in Gynecology and Obstetrics	519
Introduction	519
Biomarkers of menopause	519
Biomarkers of premenstrual dysphoric disorder	519
Biomarkers of endometriosis	520
Biomarkers for preeclampsia	520
Pathogenesis of preeclampsia.....	520
Metabolomic biomarkers in urine in preeclampsia.....	521
Protein biomarker of preeclampsia in urine.....	521
Protein biomarkers of preeclampsia in CSF.....	522

Protein HtrA1 as a biomarker for preeclampsia	522
Placental growth factor as a biomarker for preeclampsia	523
sFlt1 and soluble endoglin as biomarkers of preeclampsia	523
RNA biomarkers.....	523
Genes associated with preeclampsia.....	524
Biomarkers of premature birth	524
Proteomic biomarkers of premature birth	524
Biomarkers of oxidative stress in complicated pregnancies.....	525
Fetal biomarkers in maternal blood	525
Metabolic biomarkers of prenatal disorders in the mother.....	526
18. Biomarkers & Personalized Medicine	527
Introduction	527
Pharmacogenetics	527
Biomarkers and pharmacogenetics.....	528
Pharmacogenomics.....	529
Pharmacoproteomics	530
Single cell proteomics for personalized medicine	530
Role of biomarkers in development of personalized drugs.....	531
Metabolomic biomarker-based drug discovery	531
Use of biomarkers for developing MAb therapy in oncology	531
Biomarker tests for molecularly targeted therapies.....	532
Biobanking, biomarkers and personalized medicine in EU	533
Bioinformatics to sort biomarker data for personalized medicine	534
Biomarkers for monitoring response to therapy	535
Drug rescue by biomarker-based personalized medicine	535
Future role of biomarkers in personalized medicine	536
19. Biomarkers and Regulatory issues	537
Introduction	537
Biomarker validation	537
FDA criteria for a valid biomarker.....	537
FDA letter of support for biomarkers	539
Role of NIST in validation of cancer biomarkers	540
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays	540
National Biomarker Development Alliance	540
FDA perspective of biomarkers in clinical trials	541
FDA and predictive medicine.....	542
Biomarkers and FDA's Voluntary Genomic Data Submission	543
Role of imaging biomarkers in approval of drugs.....	543
Regulatory oversight of biomarker tests for targeted therapies	544
FDA and biomarkers	544
FDA consortium linking genetic biomarkers to serious adverse events	544
Oncology Biomarker Qualification Initiative	545
Critical Path Initiative	545
Predictive Safety Testing Consortium.....	547
The 21st Century Cures Act and biomarkers	547
From validated biomarker assay to a clinical laboratory diagnostic	548
Fast Path programs	549
Regulatory challenges in the biomarker field	549
FDA requirements of biomarkers and companion diagnostics	550
20. References.....	551

Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers	30
Table 1-2: Classification of biomarkers	30
Table 1-3: Terminology of clinically relevant biomarkers of disease	32
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors	42
Table 1-5: Comparison of various types of biomarkers	42
Table 1-6: Various "omics" technologies for discovery of biomarkers	44
Table 1-7: Role of biomarkers in translational medicine	45
Table 2-1: Classification of methods of gene expression analysis	48
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers	75
Table 2-3: Companies involved in developing molecular imaging	85
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers	109
Table 4-1: Companies using metabolomics for drug discovery	123
Table 4-2: Biomarker-based drug development at major pharmaceutical companies	124

Table 4-3: Causes of failures in clinical trials and their reduction by use of biomarkers	127
Table 5-1: Metabolic biomarkers of inflammatory diseases	141
Table 5-2: Oxidized phospholipids as biomarkers of various diseases	142
Table 5-3: Examples of biomarkers common to multiple diseases	156
Table 5-4: Examples of use of biomarkers in animal health	158
Table 6-1: Biomarkers of diabetes mellitus	162
Table 7-1: Biomarkers of Sjögren syndrome	178
Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues	184
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis.....	187
Table 9-1: Biomarkers of sepsis.....	196
Table 11-1: Biomarkers of aging.....	213
Table 12-1: Nutritional biomarkers.....	224
Table 13-1: Desirable characteristics of biomarkers for cancer	231
Table 13-2: Types of cancer biomarkers	233
Table 13-3: A classification of molecular diagnostic methods in cancer	240
Table 13-4: Cancer biomarkers used for diagnosis and therapy	270
Table 13-5: Novel biomarkers of prognosis in cancer treatment.....	276
Table 13-6: Biomarkers of brain tumors	284
Table 13-7: Biomarkers of breast cancer	292
Table 13-8: miRNA associated with breast cancer	301
Table 13-9: Biomarkers of colorectal cancer.....	311
Table 13-10: Biomarkers of lung cancer	325
Table 13-11: Classification of biomarkers of melanoma	334
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications	335
Table 13-13: Biomarkers of ovarian cancer	338
Table 13-14: Classification of biomarkers of pancreatic cancer	343
Table 13-15: Biomarkers of prostate cancer.....	348
Table 14-1: Biomarkers of cerebral metabolism	367
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF.....	380
Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease	382
Table 14-4: miRNA expression in neurodegenerative diseases	383
Table 14-5: Biomarkers of Parkinson disease	400
Table 14-6: Biomarkers of Huntington disease	407
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis.....	409
Table 14-8: Biomarkers of multiple sclerosis	416
Table 14-9: Gene expression as biomarker of response to interferon- β in multiple sclerosis	420
Table 14-10: Biomarkers of stroke.....	425
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis.....	426
Table 14-12: Biomarkers of traumatic brain injury	436
Table 14-13: Biomarkers of epilepsy	444
Table 14-14: Biomarkers of autism spectrum disorder.....	454
Table 14-15: Biomarkers of response to antidepressant treatment.....	459
Table 14-16: Biomarkers of posttraumatic stress disorder.....	462
Table 15-1: Classification of biomarkers for cardiovascular diseases.....	468
Table 15-2: Genes that cause cardiovascular diseases.....	470
Table 15-3: Biomarkers of abdominal aortic aneurysm	493
Table 15-4: Biomarkers for cardiovascular disease risk prediction	502
Table 16-1: Biomarkers of pulmonary diseases.....	509
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies	528
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine.....	530
Table 19-1: Issued letters of support for biomarkers by the FDA.....	539
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label.....	550

Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare	45
Figure 1-2: Role of biomarkers in monitoring of diseases	46
Figure 2-1: The central role of spectrometry in proteomics	57
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers	71
Figure 4-1: Role of biomarkers in drug discovery and development process	113
Figure 4-2: Onion-peel model of biomarker development.....	128
Figure 5-1: Diseases associated with myositis autoantibodies.....	157
Figure 6-1: Plasma lipids in metabolic syndrome.....	168
Figure 8-1: β -CrossLaps bone resorption biomarker assay	190
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers	247
Figure 13-2: Nanovesicles for detection of cancer biomarkers	263
Figure 13-3: Nanowire biosensor for cancer diagnosis	263
Figure 13-4: Cancer biomarker development and validation	363
Figure 14-1: Discovery and application of biomarkers in neurological diseases	365
Figure 14-2: MRI in Creutzfeldt-Jakob disease.....	415

Figure 14-3: A scheme of pathogenesis of MDD with relevant biomarkers	459
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology	469
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine	529
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment	531
Figure 18-3: Impact of biomarkers on personalized medicine	536
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing	537
Figure 19-2: Biomarker qualification pilot process at the FDA	539
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic	548